| Dr Gerald Dunham, MD | |
|
601 Ewing St, Suite C-15, Princeton, NJ 08540-2757 | |
| (609) 921-2300 | |
| (609) 921-9137 |
| Full Name | Dr Gerald Dunham |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 43 Years |
| Location | 601 Ewing St, Princeton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1528173788 | NPI | - | NPPES |
| D03362400 | Other | NJ | STATE CDS LICENSE |
| 25MA04070100 | Other | NJ | STATE MEDICAL LICENSE |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | 25MA04070100 (New Jersey) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Total Eye Care Centers Pc | 1658360425 | 19 |
| Princeton Family Care Llc | 7719175959 | 4 |
| Princeton-flemington Eye Institute,inc. | 9739282443 | 2 |
News Archive
Today, the leading provider of High-Throughput Sequencing analysis solutions, CLC bio, announced that they're collaborating with premier German sequencing service provider, imaGenes, to better support the fast growing German market of high-throughput sequencing analyses. imaGenes, will provide all customers receiving Next Generation Sequencing data with a temporary license for CLC Genomics Workbench for assembly and downstream sequence analyses.
The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.
The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.
MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.
› Verified 5 days ago
| Entity Name | Total Eye Care Centers Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1952313280 PECOS PAC ID: 1658360425 Enrollment ID: O20070216000410 |
News Archive
Today, the leading provider of High-Throughput Sequencing analysis solutions, CLC bio, announced that they're collaborating with premier German sequencing service provider, imaGenes, to better support the fast growing German market of high-throughput sequencing analyses. imaGenes, will provide all customers receiving Next Generation Sequencing data with a temporary license for CLC Genomics Workbench for assembly and downstream sequence analyses.
The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.
The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.
MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.
› Verified 5 days ago
| Entity Name | Princeton-flemington Eye Institute,inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083729271 PECOS PAC ID: 9739282443 Enrollment ID: O20070319000462 |
News Archive
Today, the leading provider of High-Throughput Sequencing analysis solutions, CLC bio, announced that they're collaborating with premier German sequencing service provider, imaGenes, to better support the fast growing German market of high-throughput sequencing analyses. imaGenes, will provide all customers receiving Next Generation Sequencing data with a temporary license for CLC Genomics Workbench for assembly and downstream sequence analyses.
The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.
The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.
MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.
› Verified 5 days ago
| Entity Name | Princeton Family Care Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1053638452 PECOS PAC ID: 7719175959 Enrollment ID: O20110103000641 |
News Archive
Today, the leading provider of High-Throughput Sequencing analysis solutions, CLC bio, announced that they're collaborating with premier German sequencing service provider, imaGenes, to better support the fast growing German market of high-throughput sequencing analyses. imaGenes, will provide all customers receiving Next Generation Sequencing data with a temporary license for CLC Genomics Workbench for assembly and downstream sequence analyses.
The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.
The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.
MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.
› Verified 5 days ago
| Entity Name | Campus Eye Group, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1447232913 PECOS PAC ID: 4789702077 Enrollment ID: O20120911000065 |
News Archive
Today, the leading provider of High-Throughput Sequencing analysis solutions, CLC bio, announced that they're collaborating with premier German sequencing service provider, imaGenes, to better support the fast growing German market of high-throughput sequencing analyses. imaGenes, will provide all customers receiving Next Generation Sequencing data with a temporary license for CLC Genomics Workbench for assembly and downstream sequence analyses.
The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.
The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.
MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gerald Dunham, MD 601 Ewing St, Suite C-15, Princeton, NJ 08540-2757 Ph: (609) 921-2300 | Dr Gerald Dunham, MD 601 Ewing St, Suite C-15, Princeton, NJ 08540-2757 Ph: (609) 921-2300 |
News Archive
Today, the leading provider of High-Throughput Sequencing analysis solutions, CLC bio, announced that they're collaborating with premier German sequencing service provider, imaGenes, to better support the fast growing German market of high-throughput sequencing analyses. imaGenes, will provide all customers receiving Next Generation Sequencing data with a temporary license for CLC Genomics Workbench for assembly and downstream sequence analyses.
The American Society for Radiation Oncology has issued a new white paper, "A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy," that recommends specific guidance to follow in the delivery of high-dose-rate (HDR) brachytherapy to improve quality and patient safety, according to the manuscript published in the March-April 2014 print issue of Practical Radiation Oncology, the official clinical practice journal of ASTRO.
The company is pleased to announce that after receiving Ethical Committee (EC) and Ministry of Health (MOH) approval, for the first human use of the company's FastSeal Bioabsorbable Vascular Access Closure System, Phase I of the First in Human (FIH) clinical testing has been completed, with 100% successful results, and no adverse effects, including post procedural discomfort.
MicroPort Scientific Corporation and Sorin Group, announced today that they have entered into a definitive agreement to form a joint venture to market and develop cardiac rhythm management devices (implantable pacemakers, defibrillators, cardiac resynchronization devices and related devices) in China. MicroPort will hold a 51 percent stake in the joint venture entity, while Sorin will hold the remaining 49 percent interest.
› Verified 5 days ago
Dr. Anita I Miedziak, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 419 North Harrison Street, Suite 104, Princeton, NJ 08540 Phone: 609-921-9437 Fax: 609-688-9941 | |
Dr. Stephen M Felton, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 419 North Harrison Street, Suite 104, Princeton, NJ 08540 Phone: 609-921-9437 Fax: 609-688-9941 | |
Dr. Richard D Reynolds, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 419 North Harrison Street, Suite 104, Princeton, NJ 08540 Phone: 609-921-9437 Fax: 609-688-9941 | |
Chirag V Patel, MD Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 601 Ewing St, Ste C 17, Princeton, NJ 08540 Phone: 609-800-2393 | |
Dr. Samuel M Liu, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 419 North Harrison Street, Suite 104, Princeton, NJ 08540 Phone: 609-921-9437 Fax: 609-688-9941 | |
Dr. Michael Y Wong, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 419 North Harrison Street, Suite 104, Princeton, NJ 08540 Phone: 609-921-9437 Fax: 609-688-9941 | |
Peter Murr, Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 419 N Harrison St Ste 104, Princeton, NJ 08540 Phone: 609-921-9437 |